Keywords
Integrated care pathways
Real life
Adherence
Self medication
Abstract
The health and economic impact of allergic diseases are increasing rapidly, and changes in management strategies are required. Its influence reduces the capacity of work and school performance by at least a third. The ICPs of the airways (integrated care pathways for respiratory diseases) are structured multidisciplinary healthcare plans, promoting the recommendations of the guidelines in local protocols and their application to clinical practice. This document presents an executive summary for Argentina, Mexico, and Spain. Next-generation ARIA guidelines are being developed for the pharmacological treatment of allergic rhinitis (AR), using the GRADE-based guidelines for AR, tested with real-life evidence provided by mobile technology with visual analogue scales. It is concluded that in the AR treatment, H1-antihistamines are less effective than intranasal corticosteroids (INCS), in severe AR the INCS represent the first line of treatment, and intranasal combination INCS + anti-H1 is more effective than monotherapy. However, according to the MASK real-life observational study, patients have poor adherence to treatment and often self-medicate, according to their needs.
References
Bousquet J, Hellings PW, Agache I, Amat F, Annesi-Maesano I, Ansotegui IJ, 4. ARIA Phase 4 (2018): change management in allergic rhinitis and asthma multimorbidity using mobile technology. J Allergy Clin Immunol. 2019;143(3):864-879. DOI: 10.1016/j.jaci.2018.08.049
Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, et al. International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. Eur Respir J. 1995;8(3):483-491. DOI: 10.1183/09031936.95.08030483
Aït-Khaled N, Pearce N, Anderson HR, Ellwood P, Montefort S, Shah J, et al. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. Allergy. 2009;64(1):123-148. DOI: 10.1111/j.1398-9995.2008.01884.x
Chong-Neto HJ, Rosário NA, Solé D, Latin American ISAAC Group. Asthma and rhinitis in South America: how different they are from other parts of the world. Allergy Asthma Immunol Res. 2012;4(2):62-67. DOI: 10.4168/aair.2012.4.2.62
Vázquez D, Medina I, Logusso G, Gattolin G, Arias S, Parisi C. Cross-sectional prevalence survey of allergic rhinitis in Argentina: Study PARA. Rev Alerg Mex. 2019;66(1):55-64. DOI: 10.29262/ram.v66i1.543
Neffen H, Mello JF, Solé D, Naspitz CK, Dodero AE, Garza HL, et al. Nasal allergies in the Latin American population: results from the Allergies in Latin America survey. Allergy Asthma Proc. 2010;31(Suppl 1):S9-S27. DOI: 10.2500/aap.2010.31.3347
Maspero JF, Jardim JR, Aranda A, Tassinari CP, González-Díaz SN, Sansores RH, et al. Insights, attitudes, and perceptions about asthma and its treatment: findings from a multinational survey of patients from Latin America. World Allergy Organ J. 2013;6(1):19. DOI: 10.1186/1939-4551-6-19
Strachan D, Sibbald B, Weiland S, Aït-Khaled N, Anabwani G, Anderson HR, et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol. 1997;8(4):161-176. DOI: 10.1111/j.1399-3038.1997.tb00156.x
Björkstén B, Clayton T, Ellwood P, Stewart A, Strachan D, ISAAC Phase III Study Group. Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol. 2008;19(2):110-124. DOI: 10.1111/j.1399-3038.2007.00601.x
Arnedo-Pena A, García-Marcos L, García-Hernández G, Aguinagua-Ontoso I, González-Díaz C, Morales-Suárez-Varela M, et al. Time trends and geographical variations in the prevalence of symptoms of allergic rhinitis in 6-7-year-old children from eight areas of Spain according to the ISAAC. An Pediatr (Barc). 2005;62(3):229-236. DOI: 10.1157/13071837
Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24(5):758-764. DOI: 10.1183/09031936.04.00013904
Vicente-Herrero MT, Prieto-Andrés L, López-González AA, Pérez-Francés C, Ramírez-Íñiguez de la Torre MV, Santamaría-Navarro C, et al. Prevalence of rhinitis and asthma respiratory symptoms in Spanish working population. Rev Med Inst Mex Seguro Soc. 2014;52(1):50-59.
Ojeda P, Sastre J, Olaguibel JM, Chivato T. Alergológica 2015: a national survey on allergic diseases in the adult Spanish population. J Investig Allergol Clin Immunol. 2018;28(3):151-164. DOI: 10.18176/jiaci.0264
Ojeda P, Ibáñez MD, Olaguibel JM, Sastre J, Chivato T. Alergológica 2015: a national survey on allergic diseases in the Spanish pediatric population. J Investig Allergol Clin Immunol. 2018;28(5):321-329. DOI: 10.18176/jiaci.0308
Valero A, Ferrer M, Sastre J, Navarro AM, Monclús L, Martí-Guadaño E, et al. A new criterion by which to discriminate between patients with moderate allergic rhinitis and patients with severe allergic rhinitis based on the Allergic Rhinitis and its Impact on Asthma severity items. J Allergy Clin Immunol. 2007;120(2):359-365. DOI: 10.1016/j.jaci.2007.04.006
ESPRINT Study Group and Investigators, Valero A, Alonso J, Antepara I, et al. Development and validation of a new Spanish instrument to measure health-related quality of life in patients with allergic rhinitis: the ESPRINT questionnaire. Value Health. 2007;10(6):466- 77. DOI: 10.1111/j.1524-4733.2007.00202.x
Janson C, Antó J, Burney P, Chinn S, de Marco R, Heinrich J, et al. The European Community Respiratory Health Survey: what are the main results so far? European Community Respiratory Health Survey II. Eur Respir J. 2001;18(3):598-611. DOI: 10.1183/09031936.01.00205801
Mancilla-Hernández E, Barnica-Alvarado RH, Morfín-Maciel B, Larenas-Linnemann D. Validation of a diagnostic questionnaire on asthma in children and adults for epidemiological studies. Rev Alerg Mex. 2014;61(2):73-80. DOI: 10.29262/ram.v61i2.29
Mancilla-Hernandez E, Medina-Ávalos MA, Barnica-Alvarado RH, Soto-Candia D, Guerrero-Venegas R, Zecua-Nájera Y. Prevalence of rhinitis allergic in populations of several states of Mexico. Rev Alerg Mex. 2015;62(3):196-201. DOI: 10.29262/ram.v62i3.107
Mancilla-Hernández E, González-Solórzano E. Prevalence of allergic rhinitis, and symptoms as indicators of risk in schoolchildren of the Puebla Northern Mountain Range. Rev Alerg Mex. 2018;65(2):140-147. DOI: 10.29262/ram.v65i2.330
Ramírez-Soto M, Bedolla-Barajas M, González-Mendoza T. Prevalence of asthma, allergic rhinitis and atopic dermatitis in school children of the Mexican Bajío region. Rev Alerg Mex. 2018;65(4):372-378. DOI: 10.29262/ram.v65i4.527
Bousquet J, Anto JM, Annesi-Maesano I, Dedeu T, Dupas E, Pepin JL, et al. POLLAR: impact of air POLLution on asthma and rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project. Clin Transl Allergy. 2018;8:36. Disponible en: https://ctajournal.biomedcentral.com/articles/10.1186/s13601-018-0221-z
Bousquet J, Arnavielhe S, Bedbrook A, Bewick M, Laune D, Mathieu-Dupas E, et al. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clin Transl Allergy. 2018;8:45. DOI: 10.1186/s13601-018-0227-6
Campbell H, Hotchkiss R, Bradshaw N, Porteous M. Integrated care pathways. BMJ. 1998;316(7125):133-137. DOI: 10.1136/bmj.316.7125.133
Hujala A, Taskinen H, Rissanen S. How to support integration to promote care for people with multimorbidity in Europe? Alemania: European Observatory Policy Briefs; 2017.
Palmer K, Marengoni A, Forjaz MJ, Jureviciene E, Laatikainen T, Mammarella F, et al. Multimorbidity care model: recommendations from the consensus meeting of the Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS). Health Policy. 2018;122(1):4-11. DOI: 10.1016/j.healthpol.2017.09.006
Bousquet J, Addis A, Adcock I, Agache I, Agusti A, Alonso A, et al. Integrated care pathways for airway diseases (AIRWAYS-ICPs). Eur Respir J. 2014;44(2):304-323. DOI: 10.1183/09031936.00014614
Meltzer EO, Wallace D, Dykewicz M, Shneyer L. Minimal Clinically Important Difference (MCID) in allergic rhinitis: agency for healthcare research and quality or anchor-based thresholds? J Allergy Clin Immunol Pract. 2016;4(4):682-688. DOI: 10.1016/j.jaip.2016.02.006
Muñoz-Cano R, Ribó P, Araujo G, Giralt E, Sánchez-López J, Valero A. Severity of allergic rhinitis impacts sleep and anxiety: results from a large Spanish cohort. Clin Transl Allergy. 2018;8:23. Disponible en: https://ctajournal.biomedcentral.com/articles/10.1186/s13601-018-0212-0
Vandenplas O, Vinnikov D, Blanc PD, Agache I, Bachert C, Bewick M, et al. Impact of rhinitis on work productivity: a systematic review. J Allergy Clin Immunol Pract. 2018;6(4):1274-1286. DOI: 10.1016/j.jaip.2017.09.002
Bousquet J, Schunemann HJ, Hellings PW, Arnavielhe S, Bachert C, Bedbrook A, et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. J Allergy Clin Immunol. 2016;138(2):367-374. DOI: 10.1016/j.jaci.2016.03.025
Courbis AL, Murray RB, Arnavielhe S, Caimmi D, Bedbrook A, van Eerd M, et al. Electronic clinical decision support system for allergic rhinitis management: MASK e-CDSS. Clin Exp Allergy. 2018;48(12):1640-1653. DOI: 10.1111/cea.13230
Use of real-world evidence to support regulatory decision-making for medical devices. EE.UU.: Guidance for Industry and Food and Drug Administration Staff; 2017.
Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence. What is it and what can it tell us? N Engl J Med. 2016;375(23):2293-2297. DOI: 10.1056/NEJMsb1609216
Briere JB, Bowrin K, Taieb V, Millier A, Toumi M, Coleman C. Meta-analyses using real-world data to generate clinical and epidemiological evidence: a systematic literature review of existing recommendations. Curr Med Res Opin. 2018;34(12):2125-2130. DOI: 10.1080/03007995.2018.1524751
Brozek JL, Akl EA, Alonso-Coello P, Lang D, Jaeschke R, Williams JW, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy. 2009;64(5):669-677. DOI: 10.1111/j.1398-9995.2009.01973.x
Brozek JL, Akl EA, Compalati E, Kreis J, Terracciano L, Fiocchi A, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy. 2011;66(5):588-595. DOI: 10.1111/j.1398-9995.2010.02530.x
Brozek JL, Akl EA, Jaeschke R, Lang DM, Bossuyt P, Glasziou P, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines: part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. Allergy. 2009;64(8):1109-1116. DOI: 10.1111/j.1398-9995.2009.02083.x
Oyinlola JO, Campbell J, Kousoulis AA. Is real world evidence influencing practice? A systematic review of CPRD research in NICE guidances. BMC Health Serv Res. 2016;16:299. DOI: 10.1186/s12913-016-1562-8
Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466-476. DOI: 10.1016/j.jaci.2010.06.047
Brozek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950-958. DOI: 10.1016/j.jaci.2017.03.050
Dykewicz MS, Wallace DV, Baroody F, Bernstein J, Craig T, Finegold I, et al. Treatment of seasonal allergic rhinitis: an evidence-based focused 2017 guideline update. Ann Allergy Asthma Immunol. 2017;119(6):489-511. DOI: 10.1016/j.anai.2017.08.012
Bousquet J, Arnavielhe S, Bedbrook A, Alexis-Alexandre G, van Eerd M, Murray R, et al. Treatment of allergic rhinitis using mobile technology with real world data: The MASK observational pilot study. Allergy. 2018;73(9):1763-1774. DOI: 10.1111/all.13406
Klimek L, Bergmann KC, Biedermann T, Bousquet J, Hellings P, Jung K, et al. Visual analogue scales (VAS): measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: position paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the working group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNOKHC). Allergo J Int. 2017;26(1):16-24. DOI: 10.1007/s40629-016-0006-7
Horak F, Bruttmann G, Pedrali P, Weeke B, Frolund L, Wolff HH, et al. A multicentric study of loratadine, terfenadine and placebo in patients with seasonal allergic rhinitis. Arzneimittelforschung. 1988;38(1):124-128.
Hampel FC, Ratner PH, van Bavel J, Amar NJ, Daftary P, Wheeler W, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol. 2010;105(2):168-173. DOI: 10.1016/j.anai.2010.06.008
Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282-1289. DOI: 10.1016/j.jaci.2012.01.077
Kaszuba SM, Baroody FM, de Tineo M, Haney L, Blair C, Naclerio RM. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med. 2001;161(21):2581-2587. DOI: 10.1001/archinte.161.21.2581
Glacy J, Putnam K, Godfrey S, Falzon L, Mauger B, Samson D, et al. Treatments for seasonal allergic rhinitis. EE.UU.: Agency for Healthcare Research and Quality; 2013.
Scadding GK, Durham SR, Mirakian R, Jones NS, Leech SC, Farooque S, et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2008;38(1):19-42. DOI: 10.1111/j.1365-2222.2007.02888.x
Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(Suppl 2):S1-S84. DOI: 10.1016/j.jaci.2008.06.003
Roberts G, Xatzipsalti M, Borrego LM, Custovic A, Halken S, Hellings PW, et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2013;68(9):1102-1116. DOI: 10.1111/all.12235.
Scadding GK. Optimal management of allergic rhinitis. Arch Dis Child. 2015;100(6):576-582. DOI: 10.1136/archdischild-2014-306300
Larenas-Linnemann D, Mayorga-Butron JL, Sánchez-González A, Ramírez-García A, Medina-Ávalos M, Figueroa-Morales MA, et al. ARIA Mexico 2014. Adaptation of the clinical practice guide ARIA 2010 for Mexico. Methodology ADAPTE. Rev Alerg Mex. 2014;61(Suppl 1):S3-S116. Disponible en: http://revistaalergia.mx/ojs/index.php/ram/article/view/52/69
Meltzer EO. Pharmacotherapeutic strategies for allergic rhinitis: matching treatment to symptoms, disease progression, and associated conditions. Allergy Asthma Proc. 2013;34(4):301-311.
Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR, et al. Clinical practice guideline: allergic rhinitis executive summary. Otolaryngol Head Neck Surg. 2015;152(2):197-206. DOI: 10.2500/aap.2013.34.3676
Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR, et al. Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg. 2015;152(Suppl 1):S1-S43. DOI: 10.1177/0194599814561600
Bousquet J, Meltzer EO, Couroux P, Koltun A, Kopietz F, Munzel U, et al. Onset of action of the fixed combination intranasal azelastine-fluticasone propionate in an allergen exposure chamber. J Allergy Clin Immunol Pract. 2018;6(5):1726-1732. DOI: 10.1016/j.jaip.2018.01.031
Bachert C, Bousquet J, Hellings P. Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management. Clin Transl Allergy. 2018;8:25. Disponible en: https://ctajournal.biomedcentral.com/articles/10.1186/s13601-018-0210-2
Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, Bousquet J, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65(4):459-466. DOI: 10.1111/j.1398-9995.2009.02325.x
Allergic rhinitis: developing drug products for treatment. Guidance for industry. EE.UU.: U.S. Department of Health and Human Services/Food and Drug Administration/Center for Drug Evaluation and Research; 2000.
Allergic rhinitis: developing drug products for treatment. Guidance for industry. EE.UU.: U.S. Department of Health and Human Services/Food and Drug Administration/Center for Drug Evaluation and Research; 2016.
Katial RK, Salapatek AM, Patel P. Establishing the onset of action of intranasal corticosteroids: is there an ideal study design? Allergy Asthma Proc. 2009;30(6):595-604. DOI: 10.2500/aap.2009.30.3291
Pfaar O, Calderon MA, Andrews CP, Angjeli E, Bergmann KC, Bonlokke JH, et al. Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future-an EAACI position paper. Allergy. 2017;72(7):1035-1042. DOI: 10.1111/all.13133
Patel P, D’Andrea C, Sacks HJ. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol. 2007;21(4):499-503. DOI: 10.2500/ajr.2007.21.3058
Patel P, Roland PS, Marple BF, Benninger PJ, Margalias H, Brubaker M, et al. An assessment of the onset and duration of action of olopatadine nasal spray. Otolaryngol Head Neck Surg. 2007;137(6):918-924. DOI: 10.1016/j.otohns.2007.08.005
Salapatek AM, Lee J, Patel D, D’Angelo P, Liu J, Zimmerer RO, et al. Solubilized nasal steroid (CDX-947) when combined in the same solution nasal spray with an antihistamine (CDX-313) provides improved, fast-acting symptom relief in patients with allergic rhinitis. Allergy Asthma Proc. 2011;32(3):221-229. DOI: 10.2500/aap.2011.32.3444
Horak F, Zieglmayer UP, Zieglmayer R, Kavina A, Marschall K, Munzel U, et al. Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. Curr Med Res Opin. 2006;22(1):151-157. DOI: 10.1185/030079906X80305
Zieglmayer P, Zieglmayer R, Bareille P, Rousell V, Salmon E, Horak F. Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber. Curr Med Res Opin. 2008;24(6):1833-1840. DOI: 10.1185/03007990802155792
Murdoch RD, Bareille P, Ignar D, Miller SR, Gupta A, Boardley R, et al. The improved efficacy of a fixed-dose combination of fluticasone furoate and levocabastine relative to the individual components in the treatment of allergic rhinitis. Clin Exp Allergy. 2015;45(8):1346-1355. DOI: 10.1111/cea.12556
Sleurs K, Seys S, Bousquet J, Fokkens W, Gorris S, Pugin B, et al. Mobile health tools for the management of chronic respiratory diseases. Allergy. 2019;74(7):1292-1306. DOI: 10.1111/all.13720
Bousquet J, Hellings PW, Agache I, Bedbrook A, Bachert C, Bergmann KC, et al. ARIA 2016: care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy. 2016;6:47. Disponible en : https://ctajournal.biomedcentral.com/articles/10.1186/s13601-016-0137-4
Bédard A, Basagaña X, Anto JM, Garcia-Aymerich J, Devillier P, Arnavielhe S, et al. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. J Allergy Clin Immunol. 2019;144(1):135-143. DOI: 10.1016/j.jaci.2019.01.053
Menditto E, Guerriero F, Orlando V, Crola C, Di Somma C, Illario M, et al. Self-assessment of adherence to medication: a case study in Campania region community-dwelling population. J Aging Res. 2015;2015:682503. DOI: 10.1155/2015/682503
Caimmi D, Baiz N, Tanno LK, Demoly P, Arnavielhe S, Murray R, et al. Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control. Clin Exp Allergy. 2017;47(12):1526-1533. DOI: 10.1111/cea.13025
Bonini M. Electronic health (e-Health): emerging role in asthma. Curr Opin Pulm Med. 2017;23(1):21-26. DOI: 10.1097/MCP.0000000000000336
Pizzulli A, Perna S, Florack J, Pizzulli A, Giordani P, Tripodi S, et al. The impact of telemonitoring on adherence to nasal corticosteroid treatment in children with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy. 2014;44(10):1246-1254. DOI: 10.1111/cea.12386
Bousquet J, Caimmi DP, Bedbrook A, Bewick M, Hellings PW, Devillier P, et al. Pilot study of mobile phone technology in allergic rhinitis in European countries: the MASK-rhinitis study. Allergy. 2017;72(6):857-865. DOI: 10.1111/all.13125
Bousquet J, Arnavielhe S, Bedbrook A, Fonseca J, Morais-Almeida M, Todo-Bom A, et al. The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study. Allergy. 2018;73(2):505-510. DOI: 10.1111/all.13307
Bousquet J, Devillier P, Anto JM, Bewick M, Haahtela T, Arnavielhe S, et al. Daily allergic multimorbidity in rhinitis using mobile technology: a novel concept of the MASK study. Allergy. 2018;73(9):1763-1774. DOI: 10.1111/all.13448
Bousquet J, VandenPlas O, Bewick M, Arnavielhe S, Bedbrook A, Murray R, et al. The Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) questionnaire using mobile technology: The MASK Study. J Investig Allergol Clin Immunol. 2018;28(1):42-44. DOI: 10.18176/jiaci.0197
Price D, Scadding G, Ryan D, Bachert C, Canonica GW, Mullol J, et al. The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. Clin Transl Allergy. 2015;5:39. Disponible en: https://ctajournal.biomedcentral.com/articles/10.1186/s13601-015-0083-6
Bousquet J, Murray R, Price D, Somekh D, Münter L, Phillips J, et al. The allergic allergist behaves like a patient. Ann Allergy Asthma Immunol. 2018;121(6):741-742. DOI: 10.1016/j.anai.2018.07.034
Couroux P, Kunjibettu S, Kunjibettu S, Hall N, Wingertzahn MA. Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2009;102(1):62-68. DOI: 10.1016/S1081-1206(10)60110-X
Bousquet J, Schünemann H, Togias A, Bachert C, Erhola M, Hellings P, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70-80. DOI: 10.1016/j.jaci.2019.06.049
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2020 Revista Alergia México